Table 2.

Several nanomedicines show promise as possible therapeutic agents for reducing cardiotoxicity

Nanomedicine	Therapeutic agent	Size (nm)	Concluding remarks	Ref.
Liposomes	Doxorubicin	98 nm	Results were encouraging when liposomal doxorubicin was used alone or when free doxorubicin and free quercetin were administered together.	62
Liposomes	Doxorubicin	-	As a first-line treatment for MBC, Myocet enhances doxorubicin's therapeutic index by lowering grade 4 neutropenia and cardiotoxicity while maintaining antitumor activity that is equivalent to that of cyclophosphamide alone.	63
Solid lipid nanoparticles	Doxorubicin	96 nm	Research suggests that RGD-DOX-SLNs might be an effective new lipid carrier for breast cancer treatment, based on anticancer findings in both vitro and vivo.	64
Solid lipid nanoparticles	Resveratrol	271 nm	Res-SLN protects the myocardium and lessens DOX-induced cardiotoxicity in mice, indicating a therapeutic benefit.	65
Solid lipid nanoparticles	Hesperidin	175 nm	The findings suggest that HES-SLN may protect the heart from DOX-induced damage by reducing oxidative stress and cell death.	66
Iron oxide nanoparticles	-	9.8 nm	Fe2O3 NPs can cure cardiovascular problems since they do not cause any major harm to normal cardiomyocytes.	67
Iron oxide nanoparticles	Epirubicin	51 nm	By analyzing tumors using MRI, this compound may effectively detect malignancies and, in vivo, limit tumor development.	68
Micelles	Green Tea Catechin, Doxorubicin	130-140 nm	The results indicated that PIC micelles derived from EGCG may successfully counteract cardiotoxicity caused by DOX and multidrug resistance.	69